Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Characterisation of the Toxoplasma gondii tyrosine transporter and its phosphorylation by the calcium-dependent protein kinase 3.

Wallbank BA, Dominicus CS, Broncel M, Legrave N, MacRae JI, Staines HM, Treeck M.

Mol Microbiol. 2018 Nov 6. doi: 10.1111/mmi.14156. [Epub ahead of print]

PMID:
30402958
2.

[The biological function and significance of IL-35 in the pathogenesis of atherosclerosis].

Staciwa M, Broncel M.

Pol Merkur Lekarski. 2018 Apr 23;44(262):161-164. Review. Polish.

PMID:
29775441
3.

Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease.

Olszewska-Banaszczyk M, Jackowska P, Gorzelak-Pabiś P, Pytel E, Koter-Michalak M, Broncel M.

Pharmacol Rep. 2018 Apr;70(2):258-262. doi: 10.1016/j.pharep.2017.11.004. Epub 2017 Nov 20.

PMID:
29475008
4.

Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.

Vyse S, McCarthy F, Broncel M, Paul A, Wong JP, Bhamra A, Huang PH.

J Proteomics. 2018 Jan 6;170:130-140. doi: 10.1016/j.jprot.2017.08.015. Epub 2017 Aug 24.

5.

IL-22 modulates inflammatory properties of human primary aortic smooth muscle cells.

Gorzelak-Pabis P, Chałubiński M, Wojdan K, Łuczak E, Borowiec M, Broncel M.

Adv Clin Exp Med. 2017 May-Jun;26(3):461-466. doi: 10.17219/acem/62218.

6.

Analysis of Phosphotyrosine Signaling Networks in Lung Cancer Cell Lines.

Broncel M, Huang PH.

Methods Mol Biol. 2017;1636:253-262. doi: 10.1007/978-1-4939-7154-1_16.

PMID:
28730484
7.

Increased plasma concentrations of interleukin 35 in patients with coronary artery disease.

Gorzelak-Pabiś P, Chalubinski M, Wojdan K, Luczak E, Duraj I, Mozdzan M, Broncel M.

Arch Med Sci. 2017 Jun;13(4):778-784. doi: 10.5114/aoms.2016.63751. Epub 2016 Nov 18.

8.

Endothelial integrity may be regulated by a specific antigen via an IgE-mediated mechanism.

Gorzelak-Pabis P, Luczak E, Wojdan K, Antosik K, Borowiec M, Broncel M, Chalubinski M.

Postepy Hig Med Dosw (Online). 2017 Mar 2;71(0):162-169.

9.

Inhibition of peptide aggregation by means of enzymatic phosphorylation.

Folmert K, Broncel M, V Berlepsch H, Ullrich CH, Siegert MA, Koksch B.

Beilstein J Org Chem. 2016 Nov 18;12:2462-2470. doi: 10.3762/bjoc.12.240. eCollection 2016.

10.

PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Banach M, Jankowski P, Jóźwiak J, Cybulska B, Windak A, Guzik T, Mamcarz A, Broncel M, Tomasik T, Rysz J, Jankowska-Zduńczyk A, Hoffman P, Mastalerz-Migas A.

Arch Med Sci. 2017 Feb 1;13(1):1-45. doi: 10.5114/aoms.2017.64712. Epub 2016 Dec 19. No abstract available.

11.

Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease.

Pytel E, Bukowska B, Koter-Michalak M, Olszewska-Banaszczyk M, Gorzelak-Pabiś P, Broncel M.

Pharmacol Rep. 2017 Feb;69(1):150-155. doi: 10.1016/j.pharep.2016.09.016. Epub 2016 Sep 21.

PMID:
27923158
12.

Innate lymphoid cells type 2 - emerging immune regulators of obesity and atherosclerosis.

Chalubinski M, Luczak E, Wojdan K, Gorzelak-Pabis P, Broncel M.

Immunol Lett. 2016 Nov;179:43-46. doi: 10.1016/j.imlet.2016.09.007. Epub 2016 Sep 16. Review.

PMID:
27646628
13.

Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.

Wong JP, Todd JR, Finetti MA, McCarthy F, Broncel M, Vyse S, Luczynski MT, Crosier S, Ryall KA, Holmes K, Payne LS, Daley F, Wai P, Jenks A, Tanos B, Tan AC, Natrajan RC, Williamson D, Huang PH.

Cell Rep. 2016 Oct 25;17(5):1265-1275. doi: 10.1016/j.celrep.2016.10.005.

14.

The Effect of Combined Ezetimibe/Atorvastatin Therapy vs. Atorvastatin Monotherapy on the Erythrocyte Membrane Structure in Patients with Coronary Artery Disease: A Pilot Study.

Jackowska P, Pytel E, Koter-Michalak M, Olszewska-Banaszczyk M, Legęza A, Broncel M.

Adv Clin Exp Med. 2016 May-Jun;25(3):433-9. doi: 10.17219/acem/34791.

15.

Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.

Gorzelak-Pabiś P, Zyzak S, Krewko Ł, Broncel M.

Pol Arch Med Wewn. 2016 Aug 9;126(7-8):494-501. doi: 10.20452/pamw.3475. Epub 2016 Aug 9.

16.

Non-sustained ventricular tachycardia during treatment of genotype 3 chronic hepatitis C - a case report.

Poliwczak AR, Białkowska-Warzecha JE, Bała A, Broncel M, Jabłkowski MS.

Pol Merkur Lekarski. 2016 Feb;40(236):94-6.

PMID:
27000812
17.

Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation.

Matusiak A, Chałubiński M, Broncel M, Rechciński T, Rudnicka K, Miszczyk E, Walencka M, Strapagiel D, Gajewski A, Chmiela M.

Arch Med Sci. 2016 Feb 1;12(1):45-54. doi: 10.5114/aoms.2015.50772. Epub 2016 Feb 2.

18.

Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases.

Pytel E, Jackowska P, Chwatko G, Olszewska-Banaszczyk M, Koter-Michalak M, Kubalczyk P, Broncel M.

Pharmacol Rep. 2016 Apr;68(2):344-8. doi: 10.1016/j.pharep.2015.08.019. Epub 2015 Sep 28.

PMID:
26922537
19.

[Obesity as a risk factor for atrial fibrillation].

Duraj I, Broncel M.

Pol Merkur Lekarski. 2016 Jan;40(235):5-8. Polish.

PMID:
26891428
20.

The Rab-binding Profiles of Bacterial Virulence Factors during Infection.

So EC, Schroeder GN, Carson D, Mattheis C, Mousnier A, Broncel M, Tate EW, Frankel G.

J Biol Chem. 2016 Mar 11;291(11):5832-43. doi: 10.1074/jbc.M115.700930. Epub 2016 Jan 11.

Supplemental Content

Loading ...
Support Center